Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.

Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.

Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems.

Neurocrine Biosciences (NASDAQ:NBIX) shares dropped 5. 8% following reports of patient deaths and serious adverse events potentially associated with Vykat, a treatment for Prader-Willi syndrome.

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.

In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, sharply higher than a year earlier and ahead of analyst expectations, with INGREZZA, CRENESSITY, and newly acquired VYKAT XR leading record sales. The company also raised its full-year INGREZZA sales guidance and reinforced its leadership bench with new senior appointments, underscoring an ambition to build a broader, multi-product neuroscience business backed by one...

Neurocrine Biosciences appointed a new Chief Business Officer and three Senior Vice Presidents to its senior leadership team. The moves come as the company advances its commercial portfolio and clinical pipeline. These leadership changes mark another step in Neurocrine Biosciences' evolution into a more diversified biopharmaceutical company. Neurocrine Biosciences, traded as NasdaqGS:NBIX, is drawing attention after this management reshuffle, which arrives alongside an active commercial...

Neurocrine Biosciences (NBIX) stock is in focus after the company reported second quarter 2026 revenue of US$959 million and net income of US$144.4 million, alongside updated full year guidance for INGREZZA. See our latest analysis for Neurocrine Biosciences. Despite strong Q2 results and higher INGREZZA guidance, Neurocrine Biosciences shares fell about 10% in the last trading day and are down around 5% over the past week. However, a 26% 3 month share price return and 29% 1 year total...

Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.

Neurocrine expands its portfolio with INGREZZA, CRENESSITY and VYKAT XR growth, while advancing pipeline catalysts and commercial momentum.

Neurocrine Biosciences Inc (NBIX) posts nearly 40% revenue growth in Q2 2026, driven by INGREZZA's record sales and successful launches of CRENESSITY and VYKAT XR.

Moby summary of Neurocrine Biosciences, Inc.'s Q2 2026 earnings call

Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.

The headline numbers for Neurocrine (NBIX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Neurocrine (NBIX) delivered earnings and revenue surprises of +26.11% and +6.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.

AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Neurocrine (NBIX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.

Neurocrine Biosciences stock has delivered an 83.9% return over the past five years. With the shares recently closing at US$172.69, the valuation picture now looks more like a hold than a clear bargain or clear stretch. The 83.9% five year return suggests investors have already been rewarded for backing Neurocrine Biosciences, so fresh buyers need to think carefully about what is already reflected in the price. The recent appointment of Samir Siddhanti as Chief Business Officer can support...

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NasdaqGS:NBIX) has appointed Samir Siddhanti as Chief Business Officer. Siddhanti will also join the company’s executive Management Committee. The new role is focused on driving enterprise growth, business development and the development pipeline. Neurocrine Biosciences, traded as NasdaqGS:NBIX, recently closed at $179.05, with the stock up 4.1% over the past week and 13.1% over the past month. Returns of 27.3% year to date and 34.9% over the past year have put the...

Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.

SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.

ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II data readout approaches and phase III enrollment advances.

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.

AI stocks have come under heavy selling pressure in the stock market, but biotechs are still catching a bid among institutional investors.

MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.

NVIDIA, Neurocrine Biosciences and Ball are highlighted for strong earnings growth, making them stocks to watch in the second half of 2026.

NVIDIA, Neurocrine and Ball screen well for earnings growth and rising estimates, highlighting stocks with improving profit expectations.

SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.

Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.